Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 7/2007

01-07-2007 | Article

Mannose-binding lectin deficiency attenuates renal changes in a streptozotocin-induced model of type 1 diabetes in mice

Authors: J. Østergaard, S. Thiel, M. Gadjeva, T. K. Hansen, R. Rasch, A. Flyvbjerg

Published in: Diabetologia | Issue 7/2007

Login to get access

Abstract

Aims/hypothesis

An increasing amount of evidence indicates that mannose-binding lectin (MBL) plays a role in the development of diabetic nephropathy. The main objective of the study was to analyse whether MBL influences the effects of diabetes on the kidneys.

Materials and methods

In one group of wild-type mice and in one group of MBL double knockout mice we induced diabetes by the use of streptozotocin as a model of type 1 diabetes. Two groups of non-diabetic mice, wild-type and MBL knockout, were also included. By two-way ANOVA we evaluated if MBL modulated the effects of diabetes by testing the interaction between diabetes and MBL.

Results

MBL interacted with the effects of diabetes on three outcome measures: kidney weight (p < 0.001), urinary albumin excretion (p = 0.001) and the expression of collagen IVα1 (Col4a1) mRNA (p = 0.002). This means that the effects that diabetes normally has on these parameters were significantly modified by MBL. MBL showed a tendency to interact with the effects of diabetes on glomerular basement membrane thickness and total mesangial volume (p = 0.065 and p = 0.063, respectively). Glomerular volume and total mesangial volume were significantly smaller in animals lacking MBL than in wild-type animals (p = 0.006 and p = 0.047, respectively).

Conclusions/interpretation

These findings, for the first time, show that the degree of kidney alteration as a consequence of diabetes is modified by MBL. These findings support a pivotal role of MBL in the development of diabetic kidney disease.
Literature
1.
Hovind P, Tarnow L, Rossing K et al (2003) Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 26:1258–1264CrossRefPubMed
2.
Yokoyama H, Okudaira M, Otani T et al (2000) Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. Kidney Int 58:302–311CrossRefPubMed
3.
Østergaard J, Hansen TK, Thiel S, Flyvbjerg A (2005) Complement activation and diabetic vascular complications. Clin Chim Acta 361:10–19CrossRefPubMed
4.
Hansen TK, Thiel S, Knudsen ST et al (2003) Elevated levels of mannan-binding lectin in patients with type 1 diabetes. J Clin Endocrinol Metab 88:4857–4861CrossRefPubMed
5.
Hansen TK, Tarnow L, Thiel S et al (2004) Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes 53:1570–1576CrossRefPubMed
6.
Saraheimo M, Forsblom C, Hansen TK et al (2004) Increased levels of mannan-binding lectin in type 1 diabetic patients with incipient and overt nephropathy. Diabetologia 48:198–202CrossRefPubMed
7.
Hovind P, Hansen TK, Tarnow L et al (2005) Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study. Diabetes 54:1523–1527CrossRefPubMed
8.
Shi L, Takahashi K, Dundee J et al (2004) Mannose-binding lectin-deficient mice are susceptible to infection with Staphylococcus aureus. J Exp Med 199:1379–1390CrossRefPubMed
9.
Jaffé M (1886) Uber den Niederschlag welchen Pikrinsäure in normalem Harn erzeugt und ueber eine neue Reaction des Kreatinins. Z Physiol Chem 10:391–400
10.
Myers GL, Miller WG, Coresh J et al (2006) Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem 52:5–18CrossRefPubMed
11.
Pagtalunan ME, Rasch R, Rennke HG, Meyer TW (1995) Morphometric analysis of effects of angiotensin II on glomerular structure in rats. Am J Physiol 268:F82–F88PubMed
12.
Jensen EB, Gundersen HJ, Osterby R (1979) Determination of membrane thickness distribution from orthogonal intercepts. J Microsc 115:19–33PubMed
13.
Lihn AS, Bruun JM, He G, Pedersen SB, Jensen PF, Richelsen B (2004) Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol 219:9–15CrossRefPubMed
14.
Turner MW (2003) The role of mannose-binding lectin in health and disease. Mol Immunol 40:423–429CrossRefPubMed
15.
Nordahl EA, Rydengard V, Nyberg P et al (2004) Activation of the complement system generates antibacterial peptides. Proc Natl Acad Sci U S A 101:16879–16884CrossRefPubMed
16.
Thiel S, Frederiksen PD, Jensenius JC (2006) Clinical manifestations of mannan-binding lectin deficiency. Mol Immunol 43:86–96CrossRefPubMed
17.
Hansen TK, Thiel S, Wouters PJ, Christiansen JS, Van den Berghe G (2003) Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 88:1082–1088CrossRefPubMed
18.
Steffensen R, Thiel S, Varming K, Jersild C, Jensenius JC (2000) Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. J Immunol Methods 241:33–42CrossRefPubMed
19.
Schrijvers BF, De Vriese AS, Flyvbjerg A (2004) From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 25:971–1010CrossRefPubMed
20.
Hong SW, Isono M, Chen S, Iglesias-De La Cruz MC, Han DC, Ziyadeh FN (2001) Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol 158:1653–1663PubMed
21.
Pankewycz OG, Guan JX, Bolton WK, Gomez A, Benedict JF (1994) Renal TGF-beta regulation in spontaneously diabetic NOD mice with correlations in mesangial cells. Kidney Int 46:748–758CrossRefPubMed
22.
Sharma K, Jin Y, Guo J, Ziyadeh FN (1996) Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45:522–530CrossRefPubMed
23.
Riser BL, Denichilo M, Cortes P et al (2000) Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 11:25–38CrossRefPubMed
24.
Twigg SM, Cao Z, MCLennan SV et al (2002) Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 143:4907–4915CrossRefPubMed
25.
van Nieuwenhoven FA, Jensen LJ, Flyvbjerg A, Goldschmeding R (2005) Imbalance of growth factor signalling in diabetic kidney disease: is connective tissue growth factor (CTGF, CCN2) the perfect intervention point? Nephrol Dial Transplant 20:6–10CrossRefPubMed
26.
Cha DR, Kang YS, Han SY et al (2004) Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats. J Endocrinol 183:183–194CrossRefPubMed
27.
Cooper ME, Vranes D, Youssef S et al (1999) Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 48:2229–2239CrossRefPubMed
28.
Senthil D, Choudhury GG, McLaurin C, Kasinath BS (2003) Vascular endothelial growth factor induces protein synthesis in renal epithelial cells: a potential role in diabetic nephropathy. Kidney Int 64:468–479CrossRefPubMed
29.
Tsuchida K, Makita Z, Yamagishi S et al (1999) Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 42:579–588CrossRefPubMed
30.
Yamamoto Y, Maeshima Y, Kitayama H et al (2004) Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes 53:1831–1840CrossRefPubMed
31.
Amemiya T, Sasamura H, Mifune M et al (1999) Vascular endothelial growth factor activates MAP kinase and enhances collagen synthesis in human mesangial cells. Kidney Int 56:2055–2063CrossRefPubMed
32.
Thomas S, Vanuystel J, Gruden G et al (2000) Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease. J Am Soc Nephrol 11:1236–1243PubMed
33.
Hamano Y, Grunkemeyer JA, Sudhakar A et al (2002) Determinants of vascular permeability in the kidney glomerulus. J Biol Chem 277:31154–31162CrossRefPubMed
34.
Kawachi H, Koike H, Shimizu F (2002) mAb 5-1-6 nephropathy and nephrin. Microsc Res Tech 57:236–240CrossRefPubMed
35.
Wartiovaara J, Ofverstedt LG, Khoshnoodi J et al (2004) Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography. J Clin Invest 114:1475–1483CrossRefPubMed
36.
Kelly DJ, Aaltonen P, Cox AJ et al (2002) Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of anti-proteinuric therapies. Nephrol Dial Transplant 17:1327–1332CrossRefPubMed
37.
Jensen LJ, Denner L, Schrijvers BF, Tilton RG, Rasch R, Flyvbjerg A (2006) Renal effects of a neutralising RAGE-antibody in long-term streptozotocin-diabetic mice. J Endocrinol 188:493–501CrossRefPubMed
38.
Acosta J, Hettinga J, Fluckiger R et al (2000) Molecular basis for a link between complement and the vascular complications of diabetes. Proc Natl Acad Sci U S A 97:5450–5455CrossRefPubMed
39.
Benzaquen LR, Nicholson-Weller A, Halperin JA (1994) Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med 179:985–992CrossRefPubMed
40.
Uesugi N, Sakata N, Nangaku M et al (2004) Possible mechanism for medial smooth muscle cell injury in diabetic nephropathy: glycoxidation-mediated local complement activation. Am J Kidney Dis 44:224–238CrossRefPubMed
41.
Qin X, Goldfine A, Krumrei N et al (2004) Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes. Diabetes 53:2653–2661CrossRefPubMed
42.
Granger CB, Mahaffey KW, Weaver WD et al (2003) Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the Complement Inhibition in Myocardial Infarction Treated with Angioplasty (COMMA) Trial. Circulation 108:1184–1190CrossRefPubMed
43.
Verrier ED, Shernan SK, Taylor KM et al (2004) Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA 291:2319–2327CrossRefPubMed
44.
Zimmerman JL, Dellinger RP, Straube RC, Levin JL (2000) Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome. Crit Care Med 28:3149–3154CrossRefPubMed
45.
Garred P, Madsen HO, Hofmann B, Svejgaard A (1995) Increased frequency of homozygosity of abnormal mannan-binding-protein alleles in patients with suspected immunodeficiency. Lancet 346:941–943CrossRefPubMed
46.
Garred P, Madsen HO, Balslev U et al (1997) Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet 349:236–240CrossRefPubMed
47.
Summerfield JA, Sumiya M, Levin M, Turner MW (1997) Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. BMJ 314:1229–1232PubMed
Metadata
Title
Mannose-binding lectin deficiency attenuates renal changes in a streptozotocin-induced model of type 1 diabetes in mice
Authors
J. Østergaard
S. Thiel
M. Gadjeva
T. K. Hansen
R. Rasch
A. Flyvbjerg
Publication date
01-07-2007
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 7/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-007-0686-0

Other articles of this Issue 7/2007

Diabetologia 7/2007 Go to the issue

Letter

Comment on: Davidson MB (2007) The dilemma of self-monitoring of blood glucose. Diabetologia 50:497–499

Article

A high incidence of type 1 diabetes and an alarming increase in the incidence of type 2 diabetes among young adults in Finland between 1992 and 1996

Short Communication

Direct rosiglitazone-induced modifications in insulin secretion, action and clearance: a single-dose hyperglycaemic clamp study

Letter

Comment on: Nauck MA, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50:259–267

Article

Acute nutrient regulation of the unfolded protein response and integrated stress response in cultured rat pancreatic islets

Commentary

Fighting the battle of the bulge: exercise training in early-onset type 2 diabetes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits